~ Dr. Saritha Ravella
Lung cancer is the one of the common cancers in incidence (Lung and bronchus cancer represents 13.3% of all new cancer cases in the U.S.) and the leading cause of cancer deaths (26.8 % of all cancer deaths are due to lung cancer). It is always exciting for us as medical oncologists when we have newer and better treatment options to offer our cancer patients.
TAGRISSO (osimertinib) is one of the new drugs recently FDA approved for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy.
TAGRISSO (osimertinib) is a kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion).
We need to confirm the presence of T790M mutation in tumor specimens before starting treatment with TAGRISSO.
The efficacy of TAGRISSO was demonstrated in two multicenter, single-arm, open-label clinical trials, Study 1 and Study 2, in patients with metastatic EGFR T790M mutation-positive NSCLC who had progressed on prior systemic therapy, including an EGFR TKI. All patients were required to have EGFR T790M mutation-positive NSCLC as detected by the cobas® EGFR mutation test and received TAGRISSO 80 mg once daily.